Drivers of Neoadjuvant Chemotherapy Delays After Diagnosis in Patients with MIBC
A study presented at the 2026 ASCO meeting reveals that Black, Hispanic, and non-commercially insured patients face a 50% higher risk of treatment delays for muscle-invasive bladder cancer. Researchers are using these findings to identify systemic barriers to timely care.
Why it matters
Identifying these disparities is essential for developing targeted interventions to improve cancer outcomes for marginalized populations.
Breast Cancer GI Cancer Colorectal Cancer GI Cancer Awareness and Advocacy GU Cancer Bladder Cancer Gyn-Onc Uterine Cancer Awareness Month Gynecologic Cancer Awareness Month Hem/Onc Blood Cancer Awareness Month GVHD Leukemia Lymphoma Myeloproliferative Neoplasms Multiple Myeloma Myelodysplastic Syndrome Myelofibrosis Sickle Cell Immunotherapy More Professional Development Patient Voice Lung Cancer Skin Cancer Other Tumor Types News Treatment Menu Home > Bladder Cancer > Drivers of Neoadjuvant Chemotherapy Delays After Diagnosis in Patients with MIBC
The article summarizes clinical research findings objectively.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in